Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

Tatsui Otsuka; Takashi Togo; Naoya Sugiyama; Kumi Uehara; Asuka Yoshimi; Aya Karashima; Hiromi Shioya; Yoshio Hirayasu

doi:10.1016/j.pnpbp.2006.10.014

Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

Tatsui Otsuka, Takashi Togo, Naoya Sugiyama, Kumi Uehara, Asuka Yoshimi, Aya Karashima, Hiromi Shioya, Yoshio Hirayasu

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT_2A and dopamine D₂ receptors, as well as a unique agonist effects on serotonin 5-HT_1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.

Original language	English
Pages (from-to)	564-566
Number of pages	3
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	31
Issue number	2
DOIs	https://doi.org/10.1016/j.pnpbp.2006.10.014
Publication status	Published - 2007 Mar 30
Externally published	Yes

Keywords

Augmentation therapy
Depression
Obsessive-compulsive disorder
Perospirone

ASJC Scopus subject areas

Pharmacology
Biological Psychiatry

Access to Document

10.1016/j.pnpbp.2006.10.014

Cite this

@article{e7ce39b9c0ae4d1ea82cebce26b56320,

title = "Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression",

abstract = "Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT2A and dopamine D2 receptors, as well as a unique agonist effects on serotonin 5-HT1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.",

keywords = "Augmentation therapy, Depression, Obsessive-compulsive disorder, Perospirone",

author = "Tatsui Otsuka and Takashi Togo and Naoya Sugiyama and Kumi Uehara and Asuka Yoshimi and Aya Karashima and Hiromi Shioya and Yoshio Hirayasu",

year = "2007",

month = mar,

day = "30",

doi = "10.1016/j.pnpbp.2006.10.014",

language = "English",

volume = "31",

pages = "564--566",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

AU - Otsuka, Tatsui

AU - Togo, Takashi

AU - Sugiyama, Naoya

AU - Uehara, Kumi

AU - Yoshimi, Asuka

AU - Karashima, Aya

AU - Shioya, Hiromi

AU - Hirayasu, Yoshio

PY - 2007/3/30

Y1 - 2007/3/30

N2 - Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT2A and dopamine D2 receptors, as well as a unique agonist effects on serotonin 5-HT1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.

AB - Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT2A and dopamine D2 receptors, as well as a unique agonist effects on serotonin 5-HT1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.

KW - Augmentation therapy

KW - Depression

KW - Obsessive-compulsive disorder

KW - Perospirone

UR - http://www.scopus.com/inward/record.url?scp=33846840714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846840714&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2006.10.014

DO - 10.1016/j.pnpbp.2006.10.014

M3 - Article

C2 - 17166643

AN - SCOPUS:33846840714

SN - 0278-5846

VL - 31

SP - 564

EP - 566

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

IS - 2

ER -

Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this